ARCHIVES

Oncologists Don’t Demand Increased Survival When Ordering Expensive Drugs, Survey Finds

This article is from The Cancer Letter archive.

Vol. 38 No. 15 | April 13, 2012

Download PDF Visit The Full Archive

Related Articles

Komen Foundation Shifts Emphasis To Underserved

May 7, 1993

Chemical, Viral Carcinogenesis Should Not Be Separated: Shimkin

July 14, 1978

FDA Approves Inlyta Pill For Renal Cell Carcinoma

January 27, 2012

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Bevacizumab And Irinotecan May Increase Survival Of GBM

October 26, 2007

RFA, “New Approaches In Surgical Oncology” Announced By DCT

December 1, 1978